SELECT DISEASE STATE
NSCLC
Addressing Barriers to Access and Improving Equity in Biomarker Testing
The use of biomarker testing and targeted therapies has become a standard of care for NSCLC. However, not all patients benefit equally from these advances and there remain notable racial, ethnic, and socioeconomic disparities related to access and utilization of these advancements in care.1 There is a need for improved strategies to address disparities and barriers related to access and use of guideline-indicated biomarker testing and targeted therapy in order to improve cancer-related outcomes in these patient populations.
Episodes
1Uptake of Biomarker Testing in Non–Small Cell Lung Cancer2Uptake of Biomarker Testing in Non–Small Cell Lung Cancer3Uptake of Biomarker Testing in Non–Small Cell Lung Cancer4Uptake of Biomarker Testing in Non–Small Cell Lung Cancer5Uptake of Biomarker Testing in Non–Small Cell Lung Cancer6Uptake of Biomarker Testing in Non–Small Cell Lung Cancer7Uptake of Biomarker Testing in Non–Small Cell Lung Cancer8Uptake of Biomarker Testing in Non–Small Cell Lung Cancer9Uptake of Biomarker Testing in Non–Small Cell Lung Cancer10Uptake of Biomarker Testing in Non–Small Cell Lung Cancer11Uptake of Biomarker Testing in Non–Small Cell Lung Cancer
References:
- Health equity in biomarker testing and targeted therapy. American Cancer Society, 2022. Accessed March 20, 2023. https://www.fightcancer.org/sites/default/files/health_equity_in_biomarker_testing_and_targeted_therapy_.pdf
© 2023 MJH Life Sciences®. Content developed independently by OncLive®.